NR1H4 and metabolic dysfunction-associated steatohepatitis: Several FXR agonists are currently undergoing clinical trials for the treatment of nonalcoholic steatohepatitis, and cholestatic liver diseases, including tropifexor (LJN452) (16, 17), cilofexor (GS9674 or Px201) (16, 17, 18, 19), nidufexor (20), and MET409 (21).